TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30655509
Drug: Second-generation antipsychotic
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotic drug amisulpride
Study: 25130768
Drug: Cold moisturizing
Normalized name: Sudafed OM Sinus Cold Moisturizing 0.05% Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold moisturizing formulation
Study: 10529659
Drug: Moderately early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately early dexamethasone group (14 days, total dose 4.75 mg/kg)
Study: 10529659
Drug: Early dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Early dexamethasone group (7 days, total dose 2.38 mg/kg)
Study: 2694418
Drug: Theophylline (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (5, 10, and 15 mg/l)
Study: 866904
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg indomethacin with 10 mg diazepam
Study: 28655793
Drug: Ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 10 mg/kg every 3 weeks for four doses, then 10 mg/kg every 12 weeks for up to 3 years
Study: 17121726
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (2 ml)
Study: 12767733
Drug: Topiramate (25-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (25-300 mg per day)
Study: 9109860
Drug: cM-T412 (anti-CD4
Approvals — FDA: no, EMA: no, PMDA: no
Description: cM-T412 (anti-CD4 antibody)
Study: 8258118
Drug: Perycit, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perycit, 500 mg, tid, for 3 months
Study: 8258118
Drug: Trental, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trental, 100 mg, tid, for 3 months
Study: 23467055
Drug: bifonazole-urea ointment
Normalized name: bifonazole / urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: bifonazole-urea ointment
Study: 23467055
Drug: 40% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% urea ointment with plastic dressing
Study: 16941973
Drug: Auricular point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular point pressing therapy
Study: 11344213
Drug: Glucosamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine infusion (4 micromol/dL.min) from 90-240 min (n=6)
Study: 11344213
Drug: Glucosamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine infusion (4 micromol/dL.min) from 0-300 min (n=6)
Study: 8157786
Drug: Thymopentin (Timunox),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (Timunox), 50 mg, thrice-weekly subcutaneous injections
Study: 2893314
Drug: High-dose intraventricular
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intraventricular bethanechol (1.75 mg/d)
Study: 29429800
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by radical surgery with or without adjuvant treatment (NACT group, n = 39)
Study: 29429800
Drug: Radical surgery
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical surgery with or without adjuvant treatment (RH group, n = 25)
Study: 16816554
Drug: Apricitabine 800
Normalized name: cobicistat 150 MG / darunavir 800 MG / emtricitabine 200 MG / tenofovir alafenamide 10 MG [Symtuza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apricitabine 800 mg/day
Study: 16816554
Drug: Apricitabine 1200
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apricitabine 1200 mg/day
Study: 16816554
Drug: Apricitabine 1600
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apricitabine 1600 mg/day
Study: 31441409
Drug: Shenfu group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu group (received 60 mL Shenfu injection infusion for 7 days)
Study: 26645521
Drug: Resistant Starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant Starch (RS2) 10 g/d for 8 weeks
Study: 21465247
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) ingestion (0.3 g kg(‐1) body weight)
Study: 2647535
Drug: 2% ketanserin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% ketanserin ointment
Study: 10884197
Drug: Cup with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cup with cluster holes for adjunctive screw fixation (n = 30)
Study: 16417773
Drug: Penyanqing Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penyanqing Capsule (PYQC), 3 times a day, 4 capsules each time, for 2 months
Study: 16417773
Drug: Fuyankang tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuyankang tablets (FYKT), 3 times a day, 6 tablets each time, for 2 months
Study: 12847648
Drug: Lösferron (ferrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lösferron (ferrous gluconate, Lilly Pharma, Hamburg) - 0.5 l
Study: 12847648
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral contrast agent
Study: 12782900
Drug: Stepped-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped-care treatment
Study: 27189657
Drug: 0.01 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mL/kg dose of 10% fluorescein sodium
Study: 27189657
Drug: 0.02 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mL/kg dose of 10% fluorescein sodium
Study: 22708649
Drug: TBV administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBV administered concurrently with PIFN (standard dosing arm)
Study: 22708649
Drug: TBV 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBV 600 mg BID monotherapy for 4 weeks followed by combination therapy with PIFN (pre-dosing arm)
Study: 20063435
Drug: S90049 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: S90049 (60 mg)
Study: 7894919
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EAP + RNB
Study: 25812128
Drug: Paced Auditory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paced Auditory Serial Addition Test (PASAT) administered to patients with MS
Study: 25812128
Drug: Paced Auditory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paced Auditory Serial Addition Test (PASAT) administered to normal controls
Study: 23669304
Drug: Alginate-antacid (Gaviscon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate-antacid (Gaviscon Double Action Liquid)
Study: 16955187
Drug: Oral inosiplex
Normalized name: Inosiplex
DrugBank: Inosine pranobex (DB13156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inosiplex (50 mg/kg/day in five divided doses for 12 weeks)
Study: 11720426
Drug: Accelerated chemotherapy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated chemotherapy with EVI and GM-CSF support (Arm B)
Study: 11720426
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy with EVI (Arm A)
Study: 11720426
Drug: Accelerated chemotherapy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated chemotherapy with EVI and oral antibiotics (Arm C)
Study: 12127385
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil treatment
Study: 8238379
Drug: FK‐453 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK‐453 (200 mg)
Study: 25675169
Drug: Transconjunctival local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transconjunctival local anesthesia with 2% lidocaine gel
Study: 22305809
Drug: Probucol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (1000 mg orally before angioplasty and 500 mg twice daily for 3 days after intervention)
Study: 18807007
Drug: Balanced 6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced 6% HES 130/0.42 plus a balanced crystalloid solution
Study: 14607210
Drug: Ximelagatran plus
Normalized name: XIMELAGATRAN
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran plus aspirin
Study: 10741624
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg)
Study: 31291710
Drug: Vaccination 2
Normalized name: VACCINES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination 2 weeks before chemotherapy (Arm A)
Study: 31291710
Drug: Vaccination on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination on the first day of chemotherapy (Arm B)
Study: 27910086
Drug: Transfusion at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion at a lower haemoglobin threshold of 70 g/l
Study: 25733335
Drug: Revised major
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revised major purgative decoction (100 ml infused through the decompression tube, three times daily)
Study: 25733335
Drug: Neostigmine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.5 mg by muscle injection, twice daily)
Study: 12466030
Drug: D-cycloserine 50
Normalized name: D-(+)-cycloserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine 50 mg/d
Study: 9642886
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT) training
Study: 9642886
Drug: Supportive-expressive dynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive dynamic therapy (SE) training
Study: 9642886
Drug: Individual drug
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual drug counseling training
Study: 9642886
Drug: Drug counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug counseling training
Study: 6759139
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg diclofenac-Na daily in 3 doses for 21 days
Study: 29395870
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy (ICBT)
Study: 27765610
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tPCS and tDCS
Study: 26074314
Drug: EPA 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA 1.8 g/day
Study: 26074314
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil 6.0 g/day
Study: 26488347
Drug: Fluoxetine 40
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 40 mg/day (bulimic patients)
Study: 17205469
Drug: Standard melarsoprol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard melarsoprol therapy (3 series of 3.6 mg/kg/day iv for 3 days, with 7-day breaks between series)
Study: 17205469
Drug: Nifurtimox monotherapy
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifurtimox monotherapy for 14 days (5 mg/kg orally 3 times per day)
Study: 9609370
Drug: micro screw
Normalized name: Lipantil Micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: micro screw with intra-oral autologous bone
Study: 2646258
Drug: Requiring ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Requiring ≥ 1/3 of treatments to satisfy the discriminant equation
Study: 21995882
Drug: Lidocaine patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine patch (5%)
Study: 16968347
Drug: naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: naltrexone (50 mg/day)
Study: 16968347
Drug: acamprosate (1998
Approvals — FDA: no, EMA: no, PMDA: no
Description: acamprosate (1998 mg/day)
Study: 12490770
Drug: Paroxetine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20-40 mg/day)
Study: 14567887
Drug: Cetrorelix (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix (GnRH antagonist) 3 mg
Study: 3549869
Drug: Amitriptyline (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (150-300 mg/day)
Study: 3549869
Drug: Desipramine (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (150-300 mg/day)
Study: 3549869
Drug: Low-dose desipramine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose desipramine (50 mg)
Study: 3549869
Drug: Low-dose amitriptyline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amitriptyline (50 mg)
Study: 17372696
Drug: Indium chloride
Normalized name: indium chloride In-111
DrugBank: Indium In-111 chloride (DB09490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indium chloride adsorbed onto activated charcoal, entrapped in cellulose acetate polymer melt; specific dosage and duration not mentioned.
Study: 15783255
Drug: Antifibrinolytic agents
Normalized name: ANTIFIBRINOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifibrinolytic agents
Study: 29304768
Drug: Long-lasting vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-lasting vaginal Lactobacillus rhamnosus BMX 54 administration (6 months)
Study: 25659520
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg rectal morphine
Study: 20580572
Drug: Propofol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5 to 3.5 mg/kg/h)
Study: 18167121
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG (LGG) 5 x 10(9) colony-forming units twice daily for 4-6 weeks before delivery and 6 months post-natal
Study: 12623165
Drug: Gliclazide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (10 microg/ml)
Study: 12623165
Drug: Gliclazide (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (5-10 microg/ml)
Study: 26905574
Drug: Preemptive etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive etoricoxib 120 mg and intraabdominal pressure of 7 mmHg
Study: 22840917
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin 2 g
Study: 18538913
Drug: GC Tooth
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC Tooth Mousse (commercial re-mineralizing treatment)
Study: 9087480
Drug: Cefdinir, 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir, 7 mg/kg of body weight twice a day for 10 days
Study: 9087480
Drug: Cephalexin, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin, 10 mg/kg four times a day for 10 days
Study: 8384645
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (5 ng/kg per min) infusion for 60 minutes
Study: 8384645
Drug: Enalaprilat (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (1 mg intravenously) administration
Study: 8384645
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control infusion
Study: 8384645
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control administration
Study: 28399799
Drug: Sugammadex 2
Normalized name: sugammadex 200 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2 mg/kg with neostigmine 50 μg/kg (Group NS)
Study: 19165436
Drug: Standard Conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Conservative Treatment (SCT)
Study: 16442888
Drug: Pravastatin, Simvastatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin, Simvastatin, Atorvastatin
Study: 15534165
Drug: Fluviral S/F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluviral S/F (Shire Biologics)
Study: 8489326
Drug: Phenelzine sulfate
Normalized name: Phenelzine Sulfate
DrugBank: Phenelzine (DB00780)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenelzine sulfate (average dose, 60 mg/d)
Study: 3031150
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone for group A
Study: 3031150
Drug: Prolonging therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonging therapy beyond 10 days by switching to the alternate corticoid drug
Study: 3031150
Drug: Initial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial therapy period
Study: 3031150
Drug: Continuing therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuing therapy beyond initial treatment
Study: 29558423
Drug: GA +
Normalized name: Sea-Omega + D Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA + Metformin (GA + Met)
Study: 22124612
Drug: Experimental gingivitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental gingivitis (E-I test quadrants) induced by oral hygiene abstention for 21 days
Study: 10360371
Drug: Lisofylline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisofylline (3 mg/kg every 6 h i.v.)
Study: 1786587
Drug: Olbetam (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olbetam (250 mg 3 x per day for 3 months)
Study: 31351488
Drug: High-dose bio-optimized
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bio-optimized Curcuma longa extract (BCL)
Study: 31351488
Drug: Low-dose bio-optimized
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bio-optimized Curcuma longa extract (BCL)
Study: 26901576
Drug: PedaTyph™ vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PedaTyph™ vaccine (2 doses at 6 weeks interval)
Study: 26901576
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (vaccines as per national guidelines)
Study: 26901576
Drug: PedaTyph™ vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PedaTyph™ vaccine
Study: 22241898
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (anthracycline-based)
Study: 3975851
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy (control group)
Study: 17392721
Drug: Laropiprant 30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laropiprant 30, 100, and 300 mg coadministered with extended-release niacin
Study: 11919330
Drug: multisensory stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: multisensory stimulation including 1 mL 33% oral glucose
Study: 10067815
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori eradication followed by daily dietary supplementation with antioxidant micronutrients
Study: 7564362
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (5 mg ramipril and 6 mg piretanide)
Study: 28596274
Drug: Nitrate supplementation
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate supplementation (70 ml, 0.4 g nitrate)
Study: 28596274
Drug: Nitrate-depleted (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-depleted (70 ml, 0 g nitrate)
Study: 25901481
Drug: Remoxy 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxy 20 mg
Study: 25901481
Drug: Remoxy 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxy 10 mg
Study: 31975502
Drug: Topical serum
Normalized name: BIOTIN 4 g in 50 mL TOPICAL OIL [Biotn Topical Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical serum containing vitamin C, vitamin E, and raspberry leaf cell culture extract
Study: 18422592
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol 1000 mg
Study: 30100336
Drug: Intravenous dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexketoprofen 50 mg
Study: 21114791
Drug: HMPL-004 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-004 1200 mg/day
Study: 21114791
Drug: Mesalazine 4500
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine 4500 mg/day
Study: 22092168
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) infusion
Study: 18049171
Drug: Midazolam (2.87±0.67
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2.87±0.67 mg)
Study: 18049171
Drug: Midazolam (1.82±0.71
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (1.82±0.71 mg) with Meperidine (42.81±14.61 mg)
Study: 7527170
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative oral dose of 400 mg lomefloxacin followed by 400 mg daily for 3 days
Study: 25556817
Drug: Glucose-only (G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-only (G)
Study: 9352870
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (IFN‐alpha) therapy
Study: 8408979
Drug: Evening light
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening light treatment (EL)
Study: 8408979
Drug: Both ML
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both ML and EL
Study: 3955198
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg micronized megestrol acetate tablet
Study: 3955198
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg megestrol acetate tablet (Megace)
Study: 19910173
Drug: Catechin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catechin (500 microg) with antitubercular treatment (ATT)
Study: 18626312
Drug: MS-275 3
Normalized name: morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MS-275 3 mg biweekly (days 1+15, arm A)